Scholarlink

<p>We studied the effect nanomicelle curcumin on oxidative stress markers, pro-inflammatory cytokines, and assisted reproductive techniques (ART) outcomes in endometriosis cases. This randomized controlled trial was conducted on 50 women with endometriosis at the age of 25–35 candidate for ART referred to Roya Infertility Center in Qom, Iran, 2022. The participants were allocated to intervention (<i>n</i> = 25) and control (<i>n</i> = 25) groups by the blocked randomization method. Nanomicelle curcumin with a dose of 120&#xa0;mg per day was given to the intervention group twice a day for 10&#xa0;weeks, and the placebo with the same dose was given to the control group. Follicular fluid (FF) samples were collected from women with endometriosis stage III/IV undergoing ART. Antioxidant enzyme (MDA, SOD, CAT, and TAC) and pro-inflammatory cytokines (IL-8 and TNF-a) were tested. ART results such as (number of oocyte received, high-quality embryo, and pregnancy outcomes) were compared between two groups. Increased serum levels of TAC, CAT, and SOD were observed after nanomicelle curcumin treatment. Furthermore, FF levels of MDA, IL-8, and TNF-a reduced significantly after treatment in nanomicelle curcumin. Nanomicelle curcumin supplementation led to an improved number of oocytes retrieved, number of mature (MII) oocytes, fertilization, cleavage, and high-quality embryos. Nanomicelle curcumin treatment can modulate stress oxidative and inflammation in endometriosis-induced infertile patients. ART outcomes also improved after nanomicelle curcumin therapy. Our results suggest that nanomicelle curcumin can be a therapeutic target for infertile patients with endometriosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanomicelle curcumin improves oxidative stress, inflammatory markers, and assisted reproductive techniques outcomes in endometriosis cases: a randomized clinical trial

  • 期刊论文

  • 发表日期：

    2025年3月15日

查看全文
  • Rahil Jannatifar,
  • Elham Asa,
  • Ebrahim Cheraghi,
  • Atefeh Verdi

摘要

We studied the effect nanomicelle curcumin on oxidative stress markers, pro-inflammatory cytokines, and assisted reproductive techniques (ART) outcomes in endometriosis cases. This randomized controlled trial was conducted on 50 women with endometriosis at the age of 25–35 candidate for ART referred to Roya Infertility Center in Qom, Iran, 2022. The participants were allocated to intervention (n = 25) and control (n = 25) groups by the blocked randomization method. Nanomicelle curcumin with a dose of 120 mg per day was given to the intervention group twice a day for 10 weeks, and the placebo with the same dose was given to the control group. Follicular fluid (FF) samples were collected from women with endometriosis stage III/IV undergoing ART. Antioxidant enzyme (MDA, SOD, CAT, and TAC) and pro-inflammatory cytokines (IL-8 and TNF-a) were tested. ART results such as (number of oocyte received, high-quality embryo, and pregnancy outcomes) were compared between two groups. Increased serum levels of TAC, CAT, and SOD were observed after nanomicelle curcumin treatment. Furthermore, FF levels of MDA, IL-8, and TNF-a reduced significantly after treatment in nanomicelle curcumin. Nanomicelle curcumin supplementation led to an improved number of oocytes retrieved, number of mature (MII) oocytes, fertilization, cleavage, and high-quality embryos. Nanomicelle curcumin treatment can modulate stress oxidative and inflammation in endometriosis-induced infertile patients. ART outcomes also improved after nanomicelle curcumin therapy. Our results suggest that nanomicelle curcumin can be a therapeutic target for infertile patients with endometriosis.